

Karsten Weller

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9306009/publications.pdf>

Version: 2024-02-01

129
papers

6,885
citations

57758

44
h-index

69250

77
g-index

137
all docs

137
docs citations

137
times ranked

3944
citing authors

#	ARTICLE	IF	CITATIONS
1	Epidemiology, comorbidities, and healthcare utilization of patients with chronic urticaria in Germany. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 91-99.	2.4	23
2	The international WAO/EAACI guideline for the management of hereditary angioedema – The 2021 revision and update. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 1961-1990.	5.7	153
3	Prevalence and factors associated with sleep disturbance in adult patients with psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 688-697.	2.4	15
4	The international WAO/EAACI guideline for the management of hereditary angioedema – The 2021 revision and update. <i>World Allergy Organization Journal</i> , 2022, 15, 100627.	3.5	37
5	Chronic spontaneous urticaria activity, impact and control as well as their changes are strongly linked, and these links are not affected by angioedema or comorbid inducible urticaria – Results from the validation of the Polish Urticaria Control Test. <i>World Allergy Organization Journal</i> , 2022, 15, 100635.	3.5	6
6	Development of the Cold Urticaria Activity Score. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 2509-2519.	5.7	5
7	Disease Impact, Diagnostic Delay, and Unmet Medical Needs of Patients With Cholinergic Urticaria in German-Speaking Countries. <i>Frontiers in Allergy</i> , 2022, 3, .	2.8	1
8	A comprehensive, tri-national, cross-sectional analysis of characteristics and impact of pruritus in psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 2064-2075.	2.4	8
9	Impact of lanadelumab on health-related quality of life in patients with hereditary angioedema in the HELP study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 1188-1198.	5.7	28
10	The Chronic Urticaria Registry: rationale, methods and initial implementation. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 721-729.	2.4	16
11	The global burden of chronic urticaria for the patient and society*. <i>British Journal of Dermatology</i> , 2021, 184, 226-236.	1.5	150
12	The characteristics and impact of pruritus in adult dermatology patients: A prospective, cross-sectional study. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 691-700.	1.2	28
13	A novel histopathological scoring system to distinguish urticarial vasculitis from chronic spontaneous urticaria. <i>Clinical and Translational Allergy</i> , 2021, 11, e12031.	3.2	18
14	Lanadelumab Efficacy, Safety, and Injection Interval Extension in HAE: A Real-Life Study. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 3744-3751.	3.8	17
15	How to Measure Disease Activity, Impact, and Control in Patients with Recurrent Wheals, Angioedema, or Both. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2151-2157.	3.8	7
16	The Diagnostic Workup in Chronic Spontaneous Urticaria – What to Test and Why. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 2274-2283.	3.8	21
17	How are patients with chronic urticaria interested in using information and communication technologies to guide their healthcare? A UCARE study. <i>World Allergy Organization Journal</i> , 2021, 14, 100542.	3.5	11
18	Assessment of urticaria using a self-reported diagnosis tool (SRUD): a multicentre validation study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e652-e654.	2.4	0

#	ARTICLE	IF	CITATIONS
19	Assessment of disease activity and quality of life in patients with recurrent bradykinin-mediated versus mast cell-mediated angioedema. <i>World Allergy Organization Journal</i> , 2021, 14, 100554.	3.5	12
20	Automatic screening of self-evaluation apps for urticaria and angioedema shows a high unmet need. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 3810-3813.	5.7	8
21	Sleep disturbance in adult dermatologic patients: A cross-sectional study on prevalence, burden, and associated factors. <i>Journal of the American Academy of Dermatology</i> , 2021, 85, 910-922.	1.2	9
22	Patient-reported Outcome Measures for Angioedema: A Literature Review. <i>Acta Dermato-Venereologica</i> , 2021, 101, adv00456.	1.3	5
23	Impact of Chronic Urticaria and How to Measure It. , 2021, , 39-56.		1
24	Evaluation of the Reliability and Validity of the Persian Version of Urticaria Control Test (UCT). <i>Iranian Journal of Allergy, Asthma and Immunology</i> , 2021, 20, 423-431.	0.4	0
25	Chronic urticaria patients are interested in apps to monitor their disease activity and control: A UCARE CURICT analysis. <i>Clinical and Translational Allergy</i> , 2021, 11, e12089.	3.2	9
26	Pruritus and sleep disturbances in patients with psoriasis. <i>Archives of Dermatological Research</i> , 2020, 312, 103-111.	1.9	32
27	Prevalence of chronic urticaria in children and adults across the globe: Systematic review with meta-analysis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 423-432.	5.7	213
28	Development of the Angioedema Control Test – A patient-reported outcome measure that assesses disease control in patients with recurrent angioedema. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1165-1177.	5.7	47
29	The Arabic Urticaria Activity Score and Chronic Urticaria Quality of Life Questionnaire: validation and correlations. <i>International Journal of Dermatology</i> , 2020, 59, 893-901.	1.0	4
30	Flare Size but Not Intensity Reflects Histamine-Induced Itch. <i>Skin Pharmacology and Physiology</i> , 2020, 33, 244-252.	2.5	3
31	Validation of the Angioedema Control Test (AECT) – A Patient-Reported Outcome Instrument for Assessing Angioedema Control. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 2050-2057.e4.	3.8	50
32	Validity, reliability, and interpretability of the Brazilian urticaria control test. <i>Allergy and Asthma Proceedings</i> , 2020, 41, e61-e66.	2.2	4
33	Urticaria: Collegium Internationale Allergologicum (CIA) Update 2020. <i>International Archives of Allergy and Immunology</i> , 2020, 181, 321-333.	2.1	108
34	The usage, quality and relevance of information and communications technologies in patients with chronic urticaria: A UCARE study. <i>World Allergy Organization Journal</i> , 2020, 13, 100475.	3.5	13
35	Dupilumab in Treatment of Chronic Prurigo: A Case Series and Literature Review. <i>Acta Dermato-Venereologica</i> , 2019, 99, 905-906.	1.3	25
36	Angioedema quality of life questionnaire (AE-QoL) - interpretability and sensitivity to change. <i>Health and Quality of Life Outcomes</i> , 2019, 17, 160.	2.4	24

#	ARTICLE	IF	CITATIONS
37	Navigating the landscape of core outcome set development in dermatology. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 297-305.	1.2	46
38	Minimal important difference of the Chronic Urticaria Quality of Life Questionnaire (CUâ€QoL). <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 2542-2544.	5.7	10
39	Comparison of pruritus and sensory qualities induced by capsaicin, histamine and cowhage. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 1755-1761.	2.4	7
40	Diagnosis and treatment of chronic inducible urticaria. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 2550-2553.	5.7	26
41	The response to treatment in chronic spontaneous urticaria depends on how it is measured. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 2055-2056.e4.	3.8	9
42	State of care for patients with systemic autoinflammatory diseases â€ Results of a tertiary care survey. <i>World Allergy Organization Journal</i> , 2019, 12, 100019.	3.5	15
43	Validation of the Turkish version of the Urticaria Control Test: Correlation with other tools and comparison between spontaneous and inducible chronic urticaria. <i>World Allergy Organization Journal</i> , 2019, 12, 100009.	3.5	22
44	Angioedema Activity Score (AAS): A Valid and Reliable Tool to Use in Asian Patients. <i>BioMed Research International</i> , 2019, 2019, 1-4.	1.9	16
45	Realâ€life treatment of patients with cholinergic urticaria in Germanâ€speaking countries. <i>JDDG - Journal of the German Society of Dermatology</i> , 2019, 17, 1141-1147.	0.8	10
46	Angioedema in chronic spontaneous urticaria is underdiagnosed and has a substantial impact: Analyses from <sc>ASSURE</sc>â€<sc>CSU</sc>. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 1724-1734.	5.7	74
47	Core outcome sets in dermatology: report from the second meeting of the International Cochrane Skin Group Core Outcome Set Initiative. <i>British Journal of Dermatology</i> , 2018, 178, e279-e285.	1.5	29
48	Core outcome sets in dermatology: report from the second meeting of the International Cochrane Skin Group Core Outcome Set Initiative. <i>British Journal of Dermatology</i> , 2018, 178, e297-e297.	1.5	18
49	Prevalence and clinical characteristics of chronic spontaneous urticaria in pediatric patients. <i>Pediatric Allergy and Immunology</i> , 2018, 29, 630-636.	2.6	57
50	Development and validation of the mastocytosis activity score. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 1489-1496.	5.7	17
51	Development and validation of the Cholinergic Urticaria Qualityâ€ofâ€Life Questionnaire (CholUâ€QoL). <i>Clinical and Experimental Allergy</i> , 2018, 48, 433-444.	2.9	31
52	The Urticaria Activity Scoreâ€Validity, Reliability, and Responsiveness. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018, 6, 1185-1190.e1.	3.8	78
53	Omalizumab rapidly improves angioedemaâ€related quality of life in adult patients with chronic spontaneous urticaria: Xâ€<sc>ACT</sc> study data. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 576-584.	5.7	51
54	European academy of dermatology and venereology European prurigo project: expert consensus on the definition, classification and terminology of chronic prurigo. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 1059-1065.	2.4	150

#	ARTICLE	IF	CITATIONS
55	Comparison and interpretability of the available urticaria activity scores. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 251-255.	5.7	50
56	Reply. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 1166-1167.	2.9	6
57	Reply to Ensina et al. <i>Pediatric Allergy and Immunology</i> , 2018, 29, 670-671.	2.6	1
58	Total IgE levels are linked to the response of chronic spontaneous urticaria patients to omalizumab. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 2406-2408.	5.7	74
59	Management of chronic spontaneous urticaria: a worldwide perspective. <i>World Allergy Organization Journal</i> , 2018, 11, 14.	3.5	28
60	Updosing of bilastine is effective in moderate to severe chronic spontaneous urticaria: A real-life study. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2018, 73, 2073-2075.	5.7	22
61	Lesions on the back of hands and female gender predispose to stigmatization in patients with psoriasis. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 648-654.e2.	1.2	59
62	Responsiveness and minimal important difference of the urticaria control test. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 1710-1713.e11.	2.9	68
63	The burden of chronic spontaneous urticaria is substantial: Real-world evidence from <scp>ASSURE</scp> & <scp>CSU</scp>. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2017, 72, 2005-2016.	5.7	197
64	Omalizumab is effective in symptomatic dermographism—results of a randomized placebo-controlled trial. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 870-873.e5.	2.9	73
65	Omalizumab is effective in cold urticaria—results of a randomized placebo-controlled trial. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 864-867.e5.	2.9	92
66	Off-label prescriptions and decisions on reimbursement requests in Germany - a retrospective analysis. <i>JDDG - Journal of the German Society of Dermatology</i> , 2017, 15, 1103-1109.	0.8	6
67	Chronic Urticaria in Children. <i>JAMA Dermatology</i> , 2017, 153, 1221.	4.1	18
68	Off-Label-Use und Entscheidungen über Anträge auf Kostenübernahme in Deutschland - eine retrospektive Analyse. <i>JDDG - Journal of the German Society of Dermatology</i> , 2017, 15, 1103-1110.	0.8	3
69	Knowledge and management of chronic spontaneous urticaria in Latin America: a cross-sectional study in Ecuador. <i>World Allergy Organization Journal</i> , 2017, 10, 21.	3.5	15
70	Clinical Measures of Chronic Urticaria. <i>Immunology and Allergy Clinics of North America</i> , 2017, 37, 35-49.	1.9	34
71	Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 1059-1061.e1.	2.9	167
72	Autoimmune chronic spontaneous urticaria: What we know and what we do not know. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 1772-1781.e1.	2.9	240

#	ARTICLE	IF	CITATIONS
73	Efficacy and safety of canakinumab in Schnitzler syndrome: A multicenter randomized placebo-controlled study. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 1311-1320.	2.9	89
74	Health-related quality of life with hereditary angioedema following prophylaxis with subcutaneous C1-inhibitor with recombinant hyaluronidase. <i>Allergy and Asthma Proceedings</i> , 2017, 38, 143-151.	2.2	28
75	Chronic urticaria in most patients is poorly controlled. <i>Journal of King Abdulaziz University, Islamic Economics</i> , 2017, 38, 1230-1236.	1.1	11
76	Antihistamine up dosing reduces disease activity in patients with difficult-to-treat cholinergic urticaria. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 1483-1485.e9.	2.9	38
77	Development and validation of the mastocytosis quality of life questionnaire: MC-QoL. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2016, 71, 869-877.	5.7	45
78	The Angioedema Quality of Life Questionnaire (AQoL) – assessment of sensitivity to change and minimal clinically important difference. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2016, 71, 1203-1209.	5.7	92
79	Report from the kick-off meeting of the Cochrane Skin Group Core Outcome Set Initiative (CSG-COUSIN). <i>British Journal of Dermatology</i> , 2016, 174, 287-295.	1.5	41
80	Antihistamine up dosing in chronic urticaria - is there enough evidence?. <i>British Journal of Dermatology</i> , 2016, 175, 1134-1135.	1.5	3
81	Subcutaneous self-injections of C1 inhibitor: an effective and safe treatment in a patient with hereditary angio-oedema. <i>Clinical and Experimental Dermatology</i> , 2016, 41, 91-93.	1.3	9
82	Heat urticaria - easy to diagnose but also to misdiagnose. <i>British Journal of Dermatology</i> , 2016, 175, 454-455.	1.5	2
83	Validity, reliability and interpretability of the Thai version of the urticaria control test (UCT). <i>Health and Quality of Life Outcomes</i> , 2016, 14, 61.	2.4	21
84	Impaired T cell-dependent protection against <i>Leishmania major</i> infection in HIV-positive patients is associated with worsened disease outcome. <i>Experimental Dermatology</i> , 2015, 24, 302-304.	2.9	4
85	Chronic urticaria: tools to aid the diagnosis and assessment of disease status in daily practice. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 38-44.	2.4	32
86	Clinically relevant outcome measures for assessing disease activity, disease control and quality of life impairment in patients with chronic spontaneous urticaria and recurrent angioedema. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2015, 15, 220-226.	2.3	27
87	Rupatadine in Established Treatment Schemes Improves Chronic Spontaneous Urticaria Symptoms and Patients' Quality of Life: a Prospective, Non-interventional Trial. <i>Dermatology and Therapy</i> , 2015, 5, 217-230.	3.0	9
88	Symptomatic dermographism: an inadequately described disease. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2015, 29, 708-712.	2.4	48
89	ASSURE-CSU: a real-world study of burden of disease in patients with symptomatic chronic spontaneous urticaria. <i>Clinical and Translational Allergy</i> , 2015, 5, 29.	3.2	45
90	Adaptación transcultural del cuestionario Urticaria Control Test del alemán al castellano. <i>Actas Dermo-sifiliográficas</i> , 2015, 106, 746-752.	0.4	22

#	ARTICLE	IF	CITATIONS
91	Cross-Cultural Adaptation of the Urticaria Control Test From German to Castilian Spanish. <i>Actas Dermo-sifiliográficas</i> , 2015, 106, 746-752.	0.4	12
92	Interleukin-31 does not induce immediate itch in atopic dermatitis patients and healthy controls after skin challenge. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2014, 69, 113-117.	5.7	108
93	Characterization of prodromal symptoms in a large population of patients with hereditary angio-oedema. <i>Clinical and Experimental Dermatology</i> , 2014, 39, 298-303.	1.3	44
94	Development and validation of the Urticaria Control Test: A patient-reported outcome instrument for assessing urticaria control. <i>Journal of Allergy and Clinical Immunology</i> , 2014, 133, 1365-1372.e6.	2.9	268
95	Management of chronic spontaneous urticaria in real life – in accordance with the guidelines? A cross-sectional physician-based survey study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, 43-50.	2.4	59
96	Selected urticaria patients benefit from a referral to tertiary care centres – results of an expert survey. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2013, 27, e8-16.	2.4	29
97	Can On-demand Non-sedating Antihistamines Improve Urticaria Symptoms? A Double-blind, Randomized, Single-dose Study. <i>Acta Dermato-Venereologica</i> , 2013, 93, 168-174.	1.3	42
98	Efficacy and safety of canakinumab in urticarial vasculitis: An open-label study. <i>Journal of Allergy and Clinical Immunology</i> , 2013, 132, 751-754.e5.	2.9	52
99	Miltefosine: a novel treatment option for mast cell-mediated diseases. <i>Journal of Dermatological Treatment</i> , 2013, 24, 244-249.	2.2	10
100	Rupatadine improves quality of life in mastocytosis: a randomized, double-blind, placebo-controlled trial. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2013, 68, 949-952.	5.7	46
101	Practical algorithm for diagnosing patients with recurrent wheals or angioedema. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2013, 68, 816-819.	5.7	53
102	German Version of ItchyQoL: Validation and Initial Clinical Findings. <i>Acta Dermato-Venereologica</i> , 2013, 93, 562-568.	1.3	53
103	Anxiety and depression seem less common in patients with autoreactive chronic spontaneous urticaria. <i>Clinical and Experimental Dermatology</i> , 2013, 38, 870-873.	1.3	9
104	Development, validation, and initial results of the Angioedema Activity Score. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2013, 68, 1185-1192.	5.7	147
105	A novel, simple, validated and reproducible instrument for assessing provocation threshold levels in patients with symptomatic dermatographism. <i>Clinical and Experimental Dermatology</i> , 2013, 38, 360-366.	1.3	35
106	Disease Activity Only Moderately Correlates with Quality of Life Impairment in Patients with Chronic Spontaneous Urticaria. <i>Dermatology</i> , 2013, 226, 371-379.	2.1	34
107	Turkish Version of the Chronic Urticaria Quality of Life Questionnaire: Cultural Adaptation, Assessment of Reliability and Validity. <i>Acta Dermato-Venereologica</i> , 2012, 92, 419-425.	1.3	36
108	Development and construct validation of the angioedema quality of life questionnaire. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2012, 67, 1289-1298.	5.7	182

#	ARTICLE	IF	CITATIONS
109	Cost-intensive, time-consuming, problematic? How physicians in private practice experience the care of urticaria patients. JDDG - Journal of the German Society of Dermatology, 2012, 10, 341-347.	0.8	13
110	Kostenintensiv, zeitaufwendig, problematisch? - Die Betreuung von Urtikariapatienten aus der Perspektive niedergelassener Ärzte. JDDG - Journal of the German Society of Dermatology, 2012, 10, 341-349.	0.8	12
111	Atopic dermatitis and allergic rhinitis – do co-effects in therapy exist?. JDDG - Journal of the German Society of Dermatology, 2012, 10, 221-239.	0.8	3
112	Efficacy and safety of the interleukin-1 antagonist rilonacept in Schnitzler syndrome: an open-label study. Allergy: European Journal of Allergy and Clinical Immunology, 2012, 67, 943-950.	5.7	110
113	Adaptation and initial results of the Polish version of the GA2LEN Chronic Urticaria Quality Of Life Questionnaire (CU-Q2oL). Journal of Dermatological Science, 2011, 62, 36-41.	1.9	28
114	Anti-Immunoglobulin E Treatment of Patients with Recalcitrant Physical Urticaria. International Archives of Allergy and Immunology, 2011, 154, 177-180.	2.1	133
115	H1-Antihistamine Up-Dosing in Chronic Spontaneous Urticaria: Patients' Perspective of Effectiveness and Side Effects – A Retrospective Survey Study. PLoS ONE, 2011, 6, e23931.	2.5	47
116	Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report1. Allergy: European Journal of Allergy and Clinical Immunology, 2011, 66, 317-330.	5.7	597
117	Chronic spontaneous urticaria in children: Itching for insight. Pediatric Allergy and Immunology, 2011, 22, 1-8.	2.6	87
118	Successful treatment of an acute attack of acquired angioedema with the bradykinin-B2-receptor antagonist icatibant. Journal of the European Academy of Dermatology and Venereology, 2011, 25, 119-120.	2.4	21
119	Chronic Spontaneous Urticaria: How to Assess Quality of Life in Patients Receiving Treatment. Archives of Dermatology, 2011, 147, 1221.	1.4	22
120	High Prevalence of Mental Disorders and Emotional Distress in Patients with Chronic Spontaneous Urticaria. Acta Dermato-Venereologica, 2011, 91, 557-561.	1.3	110
121	Results and relevance of critical temperature threshold testing in patients with acquired cold urticaria. British Journal of Dermatology, 2010, 162, 198-200.	1.5	49
122	Antihistamine-resistant urticaria factitia successfully treated with anti-immunoglobulin E therapy. Allergy: European Journal of Allergy and Clinical Immunology, 2010, 65, 1494-1495.	5.7	46
123	Effective treatment of therapy-resistant chronic spontaneous urticaria with omalizumab. Journal of Allergy and Clinical Immunology, 2010, 126, 665-666.	2.9	59
124	Miltefosine Inhibits Human Mast Cell Activation and Mediator Release Both In Vitro and In Vivo. Journal of Investigative Dermatology, 2009, 129, 496-498.	0.7	26
125	Desloratadine Inhibits Human Skin Mast Cell Activation and Histamine Release. Journal of Investigative Dermatology, 2009, 129, 2723-2726.	0.7	31
126	Control of Pseudomonas aeruginosa Skin Infections in Mice Is Mast Cell-Dependent. American Journal of Pathology, 2007, 170, 1910-1916.	3.8	80

#	ARTICLE	IF	CITATIONS
127	Acquired cold urticaria: clinical picture and update on diagnosis and treatment. Clinical and Experimental Dermatology, 2007, 32, 241-245.	1.3	105
128	Mast cells are required for normal healing of skin wounds in mice. FASEB Journal, 2006, 20, 2366-2368.	0.5	263
129	Mast cells promote homeostasis by limiting endothelin-1-induced toxicity. Nature, 2004, 432, 512-516.	27.8	275